UW Carbone Cancer Center Receives FDA Clearance to Test New Regenerative Medicine Therapy for Radiotherapy-Induced Dry Mouth
The University of Wisconsin Carbone Cancer Center has the go-ahead to start clinical trials on a first-in-human cell therapy to treat a common side effect of radiation therapy. This investigational new drug license, or IND, recently …
September 8, 2020UW Program launches first-in-US cell-therapy trial for kidney transplant patients
MADISON, Wis. – For the first time in the United States, a research team will test a personalized cell therapy to treat a common and serious complication facing kidney transplant patients. The UW Program for …
August 6, 2019Kim McDowell Hired as Associate Director of Regulatory Affairs
Dr. Kim McDowell has been appointed to oversee the regulatory affairs of the Program for Advanced Cell Therapy (PACT). Her main duties will include crafting and managing investigational new drug (IND) and investigational device exemption …
July 17, 2019PACT Names Ross O. Meyers New Director of Cell Manufacturing
The Program for Advanced Cell Therapy (PACT) has selected a new director of cell manufacturing. Ross Meyers will oversee the program’s Good Manufacturing Practice (GMP) lab operations and advanced cell manufacturing as the program works …
June 21, 2019Cellular Pharmaceuticals Meet The Wisconsin Idea
Traditionally, drug development arises from a university discovery for which a pharmaceutical company acquires the rights and thereafter navigates the path to market approval. This process of shepherding a therapeutic discovery to become a U.S. …
May 30, 2019- More News
Integrated personalized cell technologies for improving health outcomes in children and adults